טוען...
TAM Receptor Tyrosine Kinases as Emerging Targets of Innate Immune Checkpoint Blockade for Cancer Therapy
Cancer immunotherapy utilizing T cell checkpoint inhibitors has shown tremendous clinical success. Yet this mode of treatment is effective in only a subset of patients. Unresponsive patients tend to have non-T cell inflamed tumors that lack markers associated with the activation of adaptive anti-tum...
שמור ב:
| הוצא לאור ב: | Immunol Rev |
|---|---|
| Main Authors: | , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2017
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5381815/ https://ncbi.nlm.nih.gov/pubmed/28258690 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/imr.12522 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|